Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

Abstract Purpose To report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV). Methods Twenty-six eyes of 26 patients were included. Intravitreal brolucizumab 6.0 mg was administered,...

Full description

Bibliographic Details
Main Authors: Seung Wan Nam, Zeeyoon Byun, Don-Il Ham, Mingui Kong
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Ophthalmology
Subjects:
Age-related macular degeneration
Brolucizumab
Optical coherence tomography
Pigment epithelial detachment
Polypoidal choroidal vasculopathy
Online Access:https://doi.org/10.1186/s12886-022-02711-5

Internet

https://doi.org/10.1186/s12886-022-02711-5

Similar Items